Bavarian Nordic A/S

BAVA

DK0015998017

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:20:55 17/07/2024 BST			5-day change	1st Jan Change
181.3 ^DKK	-0.75%		-3.21%	+2.06%

07-01	Bavarian Nordic Turns DKK1 Billion Facility into Sustainability-linked Loan	MT
06-28	Nordic Stocks Rose Friday; Millicom International Cellular Climbed Highest	DJ

Bavarian Nordic A/S Provides Earnings Guidance for the Year of 2016

January 03, 2017 at 10:24 am

Bavarian Nordic A/Sprovided earnings guidance for the year of 2016. For the year, the company expects revenues of approximately DKK 1,000 million and a break-even result before interest and tax.

Latest news about Bavarian Nordic A/S

Bavarian Nordic Turns DKK1 Billion Facility into Sustainability-linked Loan	07-01	MT
Nordic Stocks Rose Friday; Millicom International Cellular Climbed Highest	06-28	DJ
Bavarian Nordic Donates Mpox Vaccine to Combat African Outbreak	06-28	MT
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa	06-28	CI
Congo authorities approve mpox vaccines to try to contain outbreak	06-27	RE
Congo authorities approve mpox vaccines to try to contain outbreak	06-26	RE
Bavarian Nordic Files EU Application for Chikungunya Vaccine Candidate	06-26	MT
Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema	06-26	CI
Bavarian Nordic Wraps Up US FDA's Biologics License Application for Chikungunya Vaccine Candidate	06-18	MT
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate	06-17	CI
High-risk health workers can get routine Ebola vaccine, Gavi says	06-13	RE
High-risk health workers can get routine Ebola vaccine, says Gavi	06-13	RE
Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	05-31	MT
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	05-30	MT
Bavarian Nordic A/S and Coalition for Epidemic Preparedness Innovations Partners to Advance Mpox Vaccination in Africa	05-30	CI
Bavarian Nordic’s Medical Chief to Step Down by May-end	05-21	MT
Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer	05-21	CI
Transcript : Bavarian Nordic A/S, Q1 2024 Earnings Call, May 08, 2024	05-08
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.	05-08	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024	05-08	CI
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine	04-30	MT
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve	04-29	CI
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate	04-29	MT
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate	04-29	CI

Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%). Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bavarian Nordic A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

182.7 DKK

Average target price

263.2 DKK

Spread / Average Target

+44.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAVARIAN NORDIC A/S	+2.06%	2.07B
ELI LILLY AND COMPANY	+61.53%	848B
NOVO NORDISK A/S	+34.44%	627B
JOHNSON & JOHNSON	-3.66%	363B
MERCK & CO., INC.	+15.06%	318B
ABBVIE INC.	+9.18%	299B
ROCHE HOLDING AG	+11.45%	234B
NOVARTIS AG	+15.58%	225B
AMGEN INC.	+15.67%	179B
PFIZER, INC.	+2.47%	167B

Other Pharmaceuticals